

Anesthetic Effect - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A3D67ACC99CEN.html>

Date: March 2020

Pages: 97

Price: US\$ 2,000.00 (Single User License)

ID: A3D67ACC99CEN

Abstracts

Anesthetic Effect - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 1, 4, 1, 12, 1 and 2 respectively. Similarly, the Universities

portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Anesthetic Effect - Overview
- Anesthetic Effect - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anesthetic Effect - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anesthetic Effect - Companies Involved in Therapeutics Development
- Andros Pharmaceuticals Co Ltd
- Avecho Biotechnology Ltd
- Baudax Bio Inc
- Biotts SA
- Crescita Therapeutics Inc
- Cuda Pharmaceuticals LLC
- Drawbridge Pharmaceuticals Pty Ltd
- Expanesthetics Inc
- Hangzhou Adamerck Pharmed Inc
- Hefei Cosource Pharmaceutical Inc
- Jiangsu Hengrui Medicine Co Ltd
- Lannett Co Inc
- Lee's Pharmaceutical Holdings Ltd
- LipoSeuticals Inc
- MedinCell SA
- NutriBand Inc
- Paion AG
- Physica Pharma
- Sichuan Haisco Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- SiteOne Therapeutics Inc
- Sphaera Pharma Pte Ltd

Yichang Humanwell Pharmaceutical Co Ltd

Anesthetic Effect - Drug Profiles

(lidocaine + tetracaine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alphaxalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0498 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APC-310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cyclopentol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-05 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
EXPS-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fospropofol disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HYRPB-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-100137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
morphine glucuronide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTCA-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

PHY-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropivacaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block NaV1.7 for Local Anesthetic Effect - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anesthetic Effect - Dormant Projects

Anesthetic Effect - Discontinued Products

Anesthetic Effect - Product Development Milestones

Featured News & Press Releases

Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO

Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan

Jan 13, 2020: Lannett announces FDA approval of NDA for branded anesthetic product, Cocaine Hydrochloride nasal solution 4%

Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea

Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency

Jul 16, 2019: United States Patent and Trademark Office issues U.S. patent covering an enhanced formulation of Pliaglis

Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement

Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia

Jun 10, 2019: FDA accepts filing of NDA for Remimazolam

Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA

Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial

Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea

Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia

May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia

Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting

Appendix

Methodology

Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anesthetic Effect, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Anesthetic Effect - Pipeline by Andros Pharmaceuticals Co Ltd, H1 2020

Anesthetic Effect - Pipeline by Avecho Biotechnology Ltd, H1 2020

Anesthetic Effect - Pipeline by Baudax Bio Inc, H1 2020

Anesthetic Effect - Pipeline by Biotts SA, H1 2020

Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2020

Anesthetic Effect - Pipeline by Cuda Pharmaceuticals LLC, H1 2020

Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2020

Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2020

Anesthetic Effect - Pipeline by Hangzhou Adamerck Pharmed Inc, H1 2020

Anesthetic Effect - Pipeline by Hefei Cosource Pharmaceutical Inc, H1 2020

Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Anesthetic Effect - Pipeline by Lannett Co Inc, H1 2020

Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020

Anesthetic Effect - Pipeline by LipoSeuticals Inc, H1 2020

Anesthetic Effect - Pipeline by MedinCell SA, H1 2020

Anesthetic Effect - Pipeline by NutriBand Inc, H1 2020

Anesthetic Effect - Pipeline by Paion AG, H1 2020

Anesthetic Effect - Pipeline by Physica Pharma, H1 2020

Anesthetic Effect - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H1 2020

Anesthetic Effect - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2020

Anesthetic Effect - Pipeline by SiteOne Therapeutics Inc, H1 2020

Anesthetic Effect - Pipeline by Sphaera Pharma Pte Ltd, H1 2020

Anesthetic Effect - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020

Anesthetic Effect - Dormant Projects, H1 2020

Anesthetic Effect - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anesthetic Effect - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anesthetic Effect, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Andros Pharmaceuticals Co Ltd
Avecho Biotechnology Ltd
Baudax Bio Inc
Biotts SA
Crescita Therapeutics Inc
Cuda Pharmaceuticals LLC
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Hangzhou Adamerck Pharmed Inc
Hefei Cosource Pharmaceutical Inc
Jiangsu Hengrui Medicine Co Ltd
Lannett Co Inc
Lee's Pharmaceutical Holdings Ltd
LipoSeuticals Inc
MedinCell SA
NutriBand Inc
Paion AG
Physica Pharma
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sphaera Pharma Pte Ltd
Yichang Humanwell Pharmaceutical Co Ltd

I would like to order

Product name: Anesthetic Effect - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A3D67ACC99CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3D67ACC99CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970